Recursion Pharmaceuticals, Inc. (RXRX) stock surged 7.93% in pre-market trading on Tuesday, following the release of its second-quarter 2025 financial results and updates on its clinical programs. The company reported Q2 revenue of $19.2 million, surpassing the estimate of $15.4 million, despite an earnings per share (EPS) of $(0.41) that missed the $(0.34) estimate.
Investors appeared to focus on Recursion's clinical progress, particularly the ongoing Phase 1/2 DAHLIA study for REC-1245, a potential first-in-class RBM39 degrader. The company announced that this study is currently enrolling patient populations with replication stress and DNA repair vulnerabilities. Additionally, Recursion has identified platinum-resistant ovarian cancer as the first combination cohort for its CDK7 inhibitor, REC-617, utilizing multi-omic and real-world patient data alongside causal AI modeling.
Further boosting investor confidence, Recursion reported a strong cash position of $533.8 million as of June 30, 2025. This substantial cash reserve is expected to extend the company's runway into the fourth quarter of 2027, providing ample resources for advancing its innovative drug discovery platform and clinical programs. Despite a significant net loss of $171.9 million for the quarter, the market seems to be focusing on Recursion's long-term potential and its strategic use of advanced models and platform capabilities to enhance both internal and partnered programs.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。